CONTENTS:
- 'Deaths of despair': A term that needs to be retired [Editorial]. Darke S., Farrell M., Hall W., Lappin J., p. 1072-1074.
- Taking pleasure seriously: Should alcohol research say more about fun? [Addiction opinion and debate]. Nicholls J., Hunt G., p. 1075-1081.
- Let's talk about pleasure: Bridging the sociology and public health divide. Pennay A., Livingston M., p. 1082-1083.
- Taking pleasure seriously: Should alcohol research say more about fun? 'No safe level' advocates must take note. Morris J., Davies E., p. 1084-1085.
- Decentering alcohol: Non-drug pleasure and reinforcement as an alternative target. Acuff S.F., Strickland J.C., p. 1086-1087.
- Drinking and pleasure: Interdisciplinarity points the way forward. Nicholls J., Hunt G., p. 1088-1089.
- Electronic cigarettes and subsequent cigarette smoking in young people: A systematic review. Begh R., Conde M., Fanshawe T.R., Kneale D., Shahab L., Zhu S., et al., p. 1090-1111.
- Relative risks of adverse effects across different opioid agonist treatments - A systematic review and meta-analysis. Meyer M., Strazdins E., Guessoum A., Westenberg J.N., Appenzeller-Herzog C., Cattaneo M., et al., p. 1112-1126.
- A systematic review and meta-analysis of factors associated with adolescent substance use in Africa, 2000 to 2020. Jumbe S., Mwenda Kamninga T., Kalu U.G., Nyali J., Saleh L., Newby C., et al., p. 1127-1142.
- Educational attainment as a potential effect modifier of alcohol use and 100% alcohol-attributable mortality in the United States - A longitudinal analysis of mortality linked survey data from 1997 to 2018. Probst C., Zhu Y., Kilian C., Kerr W., Rehm J., p. 1143-1155.
- Mapping corporate sponsorship of alcohol and gambling associations: An Australian pilot study. Platts C., Lacy-Nichols J., p. 1156-1166.
- Using ecological momentary assessment to quantify Δ-9-tetrahydrocannabinol and cannabidiol use across different forms of cannabis: Feasibility in a sample of Canadian young adults reporting frequent cannabis use. Coelho S.G., Rueda S., Wardell J.D., p. 1167-1181.
- Commentary on Coelho et al.: Ecological momentary assessments may be key to the future of cannabis studies. Chester L., Hebert F.O., Jutras-Aswad D., p. 1182-1183.
- Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada. Young S., Fairbairn N., Cui Z., Bach P., Mok W.Y., Budau J., et al., p. 1184-1194.
- Commentary on Young et al.: Clinical guidance is required for stimulant co-prescription with opioid agonist therapy. Ezard N., Siefried K.J., Clifford B., p. 1195-1197.
- The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021. Stringfellow E.J., Dong H., Khatami S.N., Lee H., Jalali M.S., p. 1198-1206.
- State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset. Borquez I., Williams A.R., Hu M.C., Scott M., Stewart M.T., Harpel L., et al., p. 1207-1222.
- Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial. Johnstone S., Cooper R.K., Wray J.M., Tonkin S.S., Knapp K.S., Colder C.R., et al., p. 1223-1237.
- Commentary on Johnstone et al.: Mechanisms underlying extended pre-quit varenicline treatment for smoking cessation. Rose J.E., p. 1238-1239.
- Disentangling the effects of nicotine versus non-nicotine constituents of tobacco smoke on major depressive disorder: A multivariable Mendelian randomisation study. Burke C., Taylor G., Freeman T.P., Sallis H., Wootton R.E., Munafo M.R., et al., p. 1240-1252.
- A heroin overdose laboratory model: How do escalating doses of diamorphine alter respiratory function in a diamorphine-treated population? Tas B., Kalk N.J., Chesney E., van der Waal R., Boyd A., Bell J., et al., p. 1253-1259.
- The use of financial incentives for smoking cessation in pregnant women: A parallel-group randomised controlled trial protocol. Hammersley M.L., Dekker G.A., Gurrin L.C., Hoon E.A., Schurer S., Lynch J.W., et al., p. 1260-1270.
- Recent decline in Chinese alcohol production and consumption: Potential contributing factors and the role of globally recommended measures. Tang Y.L., Wang X., Hao W., p. 1271-1275.
- Rare but relevant: The injection of tablet preparations and pulmonary hypertension. Duflou J., p. 1276-1279.
- Considerations for implementing high-dose buprenorphine for opioid use disorder. Mitragotri S., Zhu D.T., p. 1282-1283.
- Is big money distorting the global drug policy conversation? Smyth B.P., p. 1284-1285.